Zobrazeno 1 - 10
of 21
pro vyhledávání: '"Somchai, Towanabut"'
Publikováno v:
Journal of Health Science and Medical Research (JHSMR), Vol 32, Iss 4, Pp 195-206 (2014)
Objective: To develop a population pharmacokinetic model of valproic acid (VPA) and to evaluate factors influencing VPA pharmacokinetic parameters in epileptic patients. Material and Methods: Population pharmacokinetics analysis was performed using 2
Externí odkaz:
https://doaj.org/article/b09eb7d97a864ac59e3d501129608d9d
Publikováno v:
Journal of Pharmacy & Pharmaceutical Sciences, Vol 16, Iss 4 (2013)
Purpose: To determine the effects of CYP3A5 polymorphisms on carbamazepine (CBZ) pharmacokinetic parameters when CBZ is used either as monotherapy or co-administered with phenytoin (PHT), phenobarbital (PB) or valproic acid (VPA). Methods: Retrospect
Externí odkaz:
https://doaj.org/article/3c15516ae4a74577a8196ce903ae7494
Autor:
Carlos L. Chua, Chimes Study Investigators, Somchai Towanabut, K.S. Lawrence Wong, Siwaporn Chankrachang, Chun Fan Lee, Marie-Germaine Bousser, Christopher Chen, Deidre A De Silva, Narayanaswamy Venketasubramanian, Jose C. Navarro
Publikováno v:
Journal of Stroke and Cerebrovascular Diseases. 24:823-827
BackgroundStroke trials often analyze patients with heterogeneous prognoses using a single definition of outcome, which may not be applicable to all subgroups. We aimed to evaluate the treatment effects of MCL601 among patients stratified by prognosi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ef4292f48a5e7340dece5a7b34c7af5d
https://doi.org/10.1016/j.jstrokecerebrovasdis.2014.11.017
https://doi.org/10.1016/j.jstrokecerebrovasdis.2014.11.017
Autor:
Bernard P.L. Chan, Annabelle Y. Lao, Samart Nitinun, Randolph John Fangonillo, Joel M. Advincula, Thailand, Deidre A De Silva, Udaya Ranawake, Singapore, Carlos L. Chua, Teoh Hock Luen, Gaik Bee Eow, Shrikant Pande, John Harold B Hiyadan, Marie-Germaine Bousser, Herminigildo H. Gan, Niphon Poungvarin, Sri Lanka, Alejandro C. Baroque, Sherry H.Y. Young, Maria Teresa Canete, Vivek Sharma, Neil Ambasing, Nirmala Wijekoon, Ma. Cristina San Jose, Eli John Berame, Jose C. Navarro, H Asita de Silva, Sombat Muengtaweepongsa, Hui Meng Chang, Siwaporn Chankrachang, Malaysia, Johnny K. Lokin, Chimes Study Investigators, K.S. Lawrence Wong, Somchai Towanabut, Hong Kong, Rajinder Singh, Christopher Chen, N. Venketasubramanian, Chun Fan Lee, Umapathi Thirugnanam, Philippines, Marlie Jane Mamauag, Songkram Chotickanuchit, Nijasri C. Suwanwela, Ma. Socorro Sarfati, San San Tay
Publikováno v:
Stroke. 44:3580-3583
Background and Purpose— Early vascular events are an important cause of morbidity and mortality in the first 3 months after a stroke. We aimed to investigate the effects of MLC601 on the occurrence of early vascular events within 3 months of stroke
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3aeee4144afd8118394bbc4d5550d7e1
https://doi.org/10.1161/strokeaha.113.003226
https://doi.org/10.1161/strokeaha.113.003226
Autor:
Somsak Laptikultham, Somchai Towanabut, Charungthai Dejthevaporn, Poonsri Rangseekajee, Kongkiat Kulkantrakorn, Panas Tanyakitpisal, Kritsada Rodprasert, Sunsanee Pongpakdee, Suwanna Setthawatcharawanich, Bandit Thinkhamrop
Publikováno v:
Psychogeriatrics. 13:1-8
Background: Rivastigmine is a cholinesterase inhibitor for treatment of mild to moderate Alzheimer's disease (AD) and dementia associated with Parkinson's disease. The new patch formulation was recently made available. We assessed the safety, tolerab
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::12605e8aa59673990b4cf6d69b106ebb
https://doi.org/10.1111/j.1479-8301.2012.00403.x
https://doi.org/10.1111/j.1479-8301.2012.00403.x
Autor:
Arkhom Arayawichanont, Somchai Towanabut, Pasiri Sithinamsuwan, Subsai Kongsaengdao, Samart Nidhinandana, Pairoj Boonkongchuen, Niphon Poungvarin, Siwaporn Chankrachang
Publikováno v:
Headache: The Journal of Head and Face Pain. 51:52-63
(Headache 2011;51:52-63) Objective.— To evaluate the efficacy, safety, and optimum dose of a highly purified Clostridium botulinum type A toxin-hemagglutinin complex (Dysport) for migraine prophylaxis. Background.— Botulinum toxin type-A has demo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::90787c8ea34d6d3a2bd52e88344dc44c
https://doi.org/10.1111/j.1526-4610.2010.01807.x
https://doi.org/10.1111/j.1526-4610.2010.01807.x
Publikováno v:
Current Therapeutic Research. 68(5):325-337
Background: When phenytoin is prescribed for administration via nasogastric tube, immediate-release OR) phenytoin tablets are crushed before use and extended-release (ER) phenytoin capsules are opened and only the granules are used. However, it is un
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::be564c150506f3af441b17602ac33ed6
Autor:
Boonchai, Pipatvanichgul, Suchat, Hanchaiphiboolkul, Pimchanok, Puthkhao, Tasanee, Tantirittisak, Somchai, Towanabut
Publikováno v:
Journal of the Medical Association of Thailand = Chotmaihet thangphaet. 98(8)
To investigate the association of socioeconomic status (SES) (education, personal income, and occupation) with four major risk factors of stroke, those are diabetes, hypertension, hypercholesterolemia, and current smokerThe Thai Epidemiologic Stroke
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::9e3fbd642ff52df0fc9462cac1a57e36
https://pubmed.ncbi.nlm.nih.gov/26437530
https://pubmed.ncbi.nlm.nih.gov/26437530
Autor:
Somchai Towanabut, Khwanrat Wangphonphatthanasiri, Samart Nidhinandana, Tasanee Tantirittisak, Thanes Termglinchan, Pimchanok Puthkhao, Suchat Hanchaiphiboolkul, Niphon Poungvarin, Nijasri C. Suwanwela
Publikováno v:
Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association. 23(7)
Background The purpose of the study was to determine the factors predicting high estimated 10-year stroke risk based on a risk score, and among the risk factors comprising the risk score, which factors had a greater impact on the estimated risk. Meth
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8bb477728af02495b5a8f53cf5e7bf80
https://pubmed.ncbi.nlm.nih.gov/24784012
https://pubmed.ncbi.nlm.nih.gov/24784012
Autor:
Christopher L H, Chen, Sherry H Y, Young, Herminigildo H, Gan, Rajinder, Singh, Annabelle Y, Lao, Alejandro C, Baroque, Hui Meng, Chang, John Harold B, Hiyadan, Carlos L, Chua, Joel M, Advincula, Sombat, Muengtaweepongsa, Bernard P L, Chan, H Asita, de Silva, Somchai, Towanabut, Nijasri C, Suwanwela, Niphon, Poungvarin, Siwaporn, Chankrachang, K S Lawrence, Wong, Gaik Bee, Eow, Jose C, Navarro, Narayanaswamy, Venketasubramanian, Chun Fan, Lee, Marie-Germaine, Bousser, Nirmala, Eow
Publikováno v:
Stroke. 44(8)
Background and Purpose— Previous clinical studies suggested benefit for poststroke recovery when MLC601 was administered between 2 weeks and 6 months of stroke onset. The Chinese Medicine Neuroaid Efficacy on Stroke recovery (CHIMES) study tested t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5c0b90eaae4826c5f1db4b0d32910f48
https://pubmed.ncbi.nlm.nih.gov/23780952
https://pubmed.ncbi.nlm.nih.gov/23780952